Patient demographics and health plan paid costs in CIDP
We examined demographics, prevalence of comorbidities, prescribed drugs, place of service, and mean annual health plan paid costs per patient.
Results: From 6.5 million covered lives, 73 (56% men; mean age 47) met study entry criteria. The most prescribed therapies were intravenous immunoglobulin (IVIg) (26% of patients), gabapentin (26%), and prednisone (16%). The annual health plan paid cost was $56,953. Pharmacy cost was the major cost driver (57% of the total), and IVIg totaled 90% of the pharmacy costs.
Discussion: Healthcare costs for CIDP patients are substantial, with a large burden in pharmacy utilization. Studies are needed to determine optimal long‐term treatment strategies for CIDP, particularly related to IVIg. © 2013 Wiley Periodicals, Inc.
Source: Muscle and Nerve - Category: Internal Medicine Authors: Jeffrey T. Guptill, Mark B. Bromberg, Li Zhu, Bal K. Sharma, Amy R. Thompson, Andrew Krueger, Donald B. Sanders Tags: Research Article Source Type: research
More News: CIDP | Databases & Libraries | Gabapentin | Healthcare Costs | Internal Medicine | Neurontin | Prednisone | Study